141 related articles for article (PubMed ID: 36811251)
1. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
Suzuki Y; Maekawa S; Yamashita K; Osawa L; Komiyama Y; Nakakuki N; Takada H; Muraoka M; Sato M; Takano S; Fukasawa M; Yamaguchi T; Funayama S; Morisaka H; Onishi H; Enomoto N
J Gastroenterol Hepatol; 2023 Jun; 38(6):921-929. PubMed ID: 36811251
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effects of pemafibrate on metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis-4 index and the magnetic resonance imaging-aspartate aminotransferase score.
Ichikawa T; Oba H; Owada M; Watanabe K; Yoshimura T; Fuchigami A; Nakamura A
JGH Open; 2023 Dec; 7(12):959-965. PubMed ID: 38162848
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD.
Nogami A; Yoneda M; Iwaki M; Kobayashi T; Kessoku T; Honda Y; Ogawa Y; Imajo K; Higurashi T; Hosono K; Kirikoshi H; Saito S; Nakajima A
Sci Rep; 2022 Dec; 12(1):21925. PubMed ID: 36535977
[TBL] [Abstract][Full Text] [Related]
5. Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease.
Kumada T; Toyoda H; Ogawa S; Gotoh T; Suzuki Y; Sugimoto K; Yoshida Y; Kuroda H; Kamada Y; Sumida Y; Ito T; Akita T; Tanaka J
Liver Int; 2024 Jul; 44(7):1700-1714. PubMed ID: 38558221
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
7. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
9. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
[TBL] [Abstract][Full Text] [Related]
10. A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients.
Nachit M; Lanthier N; Rodriguez J; Neyrinck AM; Cani PD; Bindels LB; Hiel S; Pachikian BD; Trefois P; Thissen JP; Delzenne NM
JHEP Rep; 2021 Aug; 3(4):100323. PubMed ID: 34355155
[TBL] [Abstract][Full Text] [Related]
11. Non-Invasive Approaches to Estimate Liver Steatosis and Stiffness in Children With Non-Alcoholic Fatty Liver Disease.
Yodoshi T; Orkin S; Trout AT; Arce-Clachar AC; Bramlage K; Liu C; Fei L; Dillman JR; Xanthakos SA; Mouzaki M
J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):495-502. PubMed ID: 34908012
[TBL] [Abstract][Full Text] [Related]
12. Effect of hepatic steatosis on native T1 mapping of 3T magnetic resonance imaging in the assessment of T1 values for patients with non-alcoholic fatty liver disease.
Ahn JH; Yu JS; Park KS; Kang SH; Huh JH; Chang JS; Lee JH; Kim MY; Nickel MD; Kannengiesser S; Kim JY; Koh SB
Magn Reson Imaging; 2021 Jul; 80():1-8. PubMed ID: 33798658
[TBL] [Abstract][Full Text] [Related]
13. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
14. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
[TBL] [Abstract][Full Text] [Related]
15. Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.
Chen J; Allen AM; Therneau TM; Chen J; Li J; Hoodeshenas S; Chen J; Lu X; Zhu Z; Venkatesh SK; Song B; Ehman RL; Yin M
Eur Radiol; 2022 Feb; 32(2):950-958. PubMed ID: 34432123
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
17. A low-energy total diet replacement program demonstrates a favorable safety profile and improves liver disease severity in nonalcoholic steatohepatitis.
Koutoukidis DA; Mozes FE; Jebb SA; Tomlinson JW; Pavlides M; Saffioti F; Huntriss R; Aveyard P; Cobbold JF
Obesity (Silver Spring); 2023 Jul; 31(7):1767-1778. PubMed ID: 37368513
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study.
Yang A; Zhu X; Zhang L; Zhang Y; Zhang D; Jin M; Niu J; Zhang H; Ding Y; Lv G
Hepatol Int; 2022 Oct; 16(5):1035-1051. PubMed ID: 35829866
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease, Bone and Muscle Quality in Prolactinoma: A Pilot Study.
Eroğlu İ; Iremli BG; Erkoc A; Idilman IS; Yuce D; Kutukcu EC; Akata D; Erbas T
J Clin Densitom; 2024; 27(2):101479. PubMed ID: 38447349
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
